title: Inhibition of vasoconstriction by angiotensin receptor antagonist GR117289C in arterial grafts.
abstract: BACKGROUND
  Angiotensin II (AII) has been suggested to be one of the important factors for genesis of graft spasm in coronary artery bypass surgery. The aim of this work was to investigate the effects of the nonpeptide angiotensin receptor AT1 antagonist GR117289C on the contraction induced by AII and other vasoconstrictors in isolated human internal mammary artery (IMA) preparations.
  
  
  METHODS
  Two hundred eight IMA rings taken from 64 patients undergoing coronary artery bypass grafting were studied in organ baths. The interaction between GR117289C and AII or the other vasoconstrictors (U46619, norepinephrine, endothelin-1, and potassium chloride) was investigated in two ways.
  
  
  RESULTS
  GR117289C induced near-maximal relaxation (94.5% +/- 2.9%) in IMA rings precontracted by AII. In IMA rings incubated with 1 or 10 nmol/L GR117289C, contractile responses to AII were attenuated in a concentration-related manner, whereas the dose-response curve did not shift to the right when higher doses of AII were administered, suggesting that the AT1 receptor blockade was noncompetitive in nature. Moreover, GR117289C also induced significant relaxation (82.9% +/- 8.1%) in IMA rings precontracted by U46619, but no inhibitory responses to U46619 could be observed when IMA rings were incubated with GR117289C. GR117289C did not alter responses to potassium chloride, norepinephrine, and endothelin-1.
  
  
  CONCLUSIONS
  These results indicate that GR117289C is a potent, selective, noncompetitive AT1 receptor antagonist that may have a possible antagonistic effect on the thromboxane A2 receptor. Because AII and thromboxane A2 are important vasoconstrictors in the genesis of graft spasm, GR117289C may become an alternative treatment to relieve graft spasm.
authors.affiliation: Cardiovascular Research, The Albert Starr Academic Center For Cardiac Surgery, Providence St. Vincent Hospital, Portland, Oregon, USA.
authors.forename: M H
authors.initials: MH
authors.lastname: Liu
authors.forename: H S
authors.initials: HS
authors.lastname: Floten
authors.forename: A P
authors.initials: AP
authors.lastname: Furnary
authors.forename: A P
authors.initials: AP
authors.lastname: Yim
authors.forename: G W
authors.initials: GW
authors.lastname: He
mesh_terms: D000368:Aged; D000804:Angiotensin II / Q000494:pharmacology; D001026:Coronary Artery Bypass; D046508:Culture Techniques; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007387:Internal Mammary-Coronary Artery Anastomosis; D008297:Male; D008323:Mammary Arteries / Q000187:drug effects*; D008875:Middle Aged; D009539:Nicotinic Acids / Q000494:pharmacology*; D011945:Receptors, Angiotensin / Q000187:drug effects*; D013777:Tetrazoles / Q000494:pharmacology*; D014661:Vasoconstriction / Q000187:drug effects*; D014662:Vasoconstrictor Agents / Q000494:pharmacology
chemical_list: D009539:Nicotinic Acids; D011945:Receptors, Angiotensin; D013777:Tetrazoles; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; C078790:GR 117289